Frontline Therapy in de Novo Multiple Myeloma Patients Under 65
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2 study is to evaluate the efficacy and safety of treatment with
bortezomib, lenalidomide and dexamethasone in patients with untreated multiple myeloma. This
study will evaluate whether the addition of lenalidomide to bortezomib and dexamethasone will
increase the Complete Response (CR)/ very good partial response (VGPR) rate before and after
High Dose Therapy (HDT) with ASCT.